stockrowImmunome, Inc. (IMNM) vs Vir Biotechnology, Inc. (VIR)
- Immunome, Inc. IMNM 19.11 +2.47%
- Vir Biotechnology, Inc. VIR 13.12 −0.23%
Immunome, Inc. and Vir Biotechnology, Inc. are both Biotechnology companies. Immunome, Inc. and Vir Biotechnology, Inc. are of similar size ($2.3B and $2.2B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,696.0% against 16.7%. Immunome, Inc. has the higher net margin (0.00% vs −61.0%) and the higher return on invested capital (0.00% vs −30.3%). Across the 16 metrics below, Vir Biotechnology, Inc. leads on 9 and Immunome, Inc. on 7.
Valuation
Profitability
| Metric | IMNM | VIR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 99.99% | 68.81% |
| Operating margin | 0.00% | (69.82%) | 0.00% |
| Net margin | 0.00% | (61.03%) | 0.00% |
| Free cash flow margin | 0.00% | (46.87%) | 0.00% |
| Return on equity | (78.71%) | (21.84%) | (50.30%) |
| Return on assets | (70.23%) | (17.34%) | (45.47%) |
| Return on invested capital | 0.00% | (30.32%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack